MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cai, G.
Right arrow Articles by Friedman, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cai, G.
Right arrow Articles by Friedman, E.

Vol. 56, Issue 5, 989-996, November 1999

Inverse Agonist Properties of Dopaminergic Antagonists at the D1A Dopamine Receptor: Uncoupling of the D1A Dopamine Receptor from Gs Protein

Guoping Cai, Hakan Gurdal, Candyce Smith, Hoau-Yan Wang, and Eitan Friedman

Laboratory of Molecular Pharmacology, Department of Pharmacology, MCP Hahnemann School of Medicine, Philadelphia, Pennsylvania, (G.C., H.G., C.S., H.Y.W., E.F.); Department of Pharmacology, Medical Faculty of Ankara University, Ankara, Turkey (H.G.)

The interaction of dopaminergic antagonists with the D1A dopamine receptor was assessed in PC2 cells that transiently express this receptor. The maximal binding and dissociation constants for the D1A dopamine receptor, using the ligand [125I]SCH23982 were 0.38 ± 0.09 nM and 1 to 4 pmol/mg, respectively, when assessed 48 h after transfection with cDNA encoding the rat D1A receptor. Basal adenylyl cyclase activity increased 50 to 60% in membranes of transfected PC2 cells compared with control membranes. The dopaminergic antagonists clozapine, cis-flupenthixol, (+)-butaclamol, haloperidol, chlorpromazine, and fluphenazine inhibited constitutive adenylyl cyclase activity in membranes of cells expressing the D1A receptor. SCH23390, a selective D1 dopamine receptor antagonist, and (-)-butaclamol did not alter basal cyclase activity, whereas dopamine increased enzyme activity in membranes expressing the D1A dopamine receptor. The coupling of D1A receptors with Gs proteins was examined by immunoprecipitation of membrane Gsalpha followed by immunoblotting with a D1A dopamine receptor monoclonal antibody. Clozapine, cis-flupenthixol, (+)-butaclamol, haloperidol, and fluphenazine but not SCH23390 or (-)-butaclamol decreased D1A receptor-Gsalpha coupling by 70 to 80%, and SCH23390 was able to prevent the receptor-Gsalpha uncoupling induced by haloperidol or clozapine. These results indicate that some dopaminergic antagonists suppress basal signal transduction and behave as inverse agonists at the D1A dopamine receptor. This action of the dopamine receptor antagonists may contribute to their antidopaminergic properties that seem to underlie their clinical actions as antipsychotic drugs.

Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
M. J. Millan, C. M. la Cour, F. Novi, R. Maggio, V. Audinot, A. Newman-Tancredi, D. Cussac, V. Pasteau, J.-A. Boutin, T. Dubuffet, et al.
S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], A Preferential Dopamine D3 versus D2 Receptor Antagonist and Potential Antipsychotic Agent: I. Receptor-Binding Profile and Functional Actions at G-Protein-Coupled Receptors
J. Pharmacol. Exp. Ther., February 1, 2008; 324(2): 587 - 599.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
W. H. Bisson, A. V. Cheltsov, N. Bruey-Sedano, B. Lin, J. Chen, N. Goldberger, L. T. May, A. Christopoulos, J. T. Dalton, P. M. Sexton, et al.
Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs
PNAS, July 17, 2007; 104(29): 11927 - 11932.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
M. M. C. Kong, T. Fan, G. Varghese, B. F. O'Dowd, and S. R. George
Agonist-Induced Cell Surface Trafficking of an Intracellularly Sequestered D1 Dopamine Receptor Homo-Oligomer
Mol. Pharmacol., July 1, 2006; 70(1): 78 - 89.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
E. M. Jutkiewicz and J. Bergman
Effects of Dopamine D1 Ligands on Eye Blinking in Monkeys: Efficacy, Antagonism, and D1/D2 Interactions
J. Pharmacol. Exp. Ther., December 1, 2004; 311(3): 1008 - 1015.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
T. Kenakin
Efficacy as a Vector: the Relative Prevalence and Paucity of Inverse Agonism
Mol. Pharmacol., January 1, 2004; 65(1): 2 - 11.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
G. Cai, H.-Y. Wang, and E. Friedman
Increased Dopamine Receptor Signaling and Dopamine Receptor-G Protein Coupling in Denervated Striatum
J. Pharmacol. Exp. Ther., September 1, 2002; 302(3): 1105 - 1112.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
E. V. Kuzhikandathil and G. S. Oxford
Classic D1 Dopamine Receptor Antagonist R-(+)-7-Chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride (SCH23390) Directly Inhibits G Protein-Coupled Inwardly Rectifying Potassium Channels
Mol. Pharmacol., July 1, 2002; 62(1): 119 - 126.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics